https://pure.psu.edu/en/publications/breakthrough-covid-19-infections-among-health-care-workers-after-/
Breakthrough COVID-19 infections among health care workers after two doses of ChAdOx1 nCoV-19...
https://www.research.ed.ac.uk/en/publications/waning-of-first-and-second-dose-chadox1-and-bnt162b2-covid-19-vac/
Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial...
https://oru.diva-portal.org/smash/record.jsf?faces-redirect=true&language=sv&searchType=SIMPLE&query=&af=%5B%5D&aq=%5B%5B%5D%5D&aq2=%5B%5B%5D%5D&aqe=%5B%5D&pid=diva2%3A1583584&noOfRows=50&sortOrder=author_sort_asc&sortOrder2=title_sort_asc&onlyFullText=false&sf=all
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
ncovmrnavaccination
https://usher.ed.ac.uk/eave-ii/connected-projects/dac-vap-2/dac-vap-ii-our-publications/waning-first-second-pfizer-oxford-astrazeneca-uk
Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations across the UK | EAVE II...
October 2022: Study finds that protection provided by first and second doses of Oxford-AstraZeneca ChAdOx1, as well as first dose of Pfizer BioNTech BNT162b2...
https://usher.ed.ac.uk/eave-ii/connected-projects/dac-vap/our-publications/dac-vap-first-dose-vaccines-cvst
First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis | EAVE...
February 2022: Research published in PLOS Medicine uses data from England, Scotland and Wales to look at possible links between having a rare type of blood...
https://umu.diva-portal.org/smash/record.jsf?faces-redirect=true&language=en&searchType=SIMPLE&query=&af=%5B%5D&aq=%5B%5B%5D%5D&aq2=%5B%5B%5D%5D&aqe=%5B%5D&pid=diva2%3A1592385&noOfRows=50&sortOrder=author_sort_asc&sortOrder2=title_sort_asc&onlyFullText=false&sf=all
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
ncovmrnavaccination
https://oru.diva-portal.org/smash/record.jsf?pid=diva2:1583584
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
ncovmrnavaccination
https://adisinsight.springer.com/trials/700352899?error=cookies_not_supported&code=c9b49284-abd3-4573-bf86-eecacc84e737
Assessment of risk of adverse events post the BNT162b2, CoronaVac, and ChAdOx1 vaccinations in...
To assess the risk of adverse events post the BNT162b2, CoronaVac, and ChAdOx1 vaccinations in Malaysia. To assess he incidence of events assessed in risk
https://pubmed.ncbi.nlm.nih.gov/34350668/
Onset/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine...
Onset/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca/Covishield): Report of two cases
https://usher.ed.ac.uk/eave-ii/key-outputs/our-publications/first-dose-adverse-events
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and...
June 2021: EAVE II study of 2.53 million first COVID-19 vaccine doses across Scotland shows small increases in risk for some adverse events following...
firstdosecovidvaccines
https://kth.diva-portal.org/smash/record.jsf?pid=diva2:1595724
Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously...
https://covid-vaccine.canada.ca/covishield/product-details
COVISHIELD (ChAdOx1-S [recombinant]) | COVID-19 vaccines and treatments portal
Information about COVISHIELD (ChAdOx1-S [recombinant]) authorized by Health Canada as a Vaccine for COVID-19.
covishieldrecombinantcovidvaccinestreatments